Monitor for Nasdaq delisting risk due to continued non-compliance with listing requirements, watch for dilution from equity line draws and convertible note conversions, and assess whether the company can improve fundamentals to address its substantial debt burden.
Executive Summary
Trinity Biotech is registering up to 35.3 million American Depositary Shares (ADSs) for resale by a selling securityholder, YA II PN, LTD., under a Standby Equity Purchase Agreement. The company may raise up to $25 million by selling ADSs to the investor at a discount to market price over a three-year period. The stock is under Nasdaq compliance review for low bid price and market value, and the company has substantial debt of $134.58 million.
Key Facts
- Company entered into Standby Equity Purchase Agreement with YA II PN, LTD. to potentially raise up to $25 million by selling ADSs at a discount (95-97% of VWAP)
- Selling securityholder may resell up to 35,282,966 ADSs (representing 705.7 million ordinary shares) in the public market
- Company will not receive proceeds from resale by selling securityholder, only from direct sales to the investor
- As of December 31, 2025, company had total indebtedness of approximately $134.58 million
- Company received Nasdaq deficiency notices for failing to maintain $1.00 minimum bid price and $15 million minimum market value of publicly held shares
- On February 24, 2026, closing price of ADS was $0.75, below Nasdaq's $1.00 minimum requirement
Financial Impact
Up to $25 million in potential gross proceeds from equity line financing, but substantial dilution expected from issuance of up to 705.7 million ordinary shares and existing convertible instruments
Risk Factors
- Potential delisting from Nasdaq if minimum bid price and market value requirements are not met by August 2026
- Significant shareholder dilution from equity line financing and conversion of existing convertible instruments (up to 1.4 billion additional shares)
- High debt burden of $134.58 million that could impair financial flexibility and access to capital
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| F-1 Filing (Primary) | 0001178913-26-000637 |
| Exhibit: exhibit_5-1.htm | 0001178913-26-000637 |
| Exhibit: ex107.htm | 0001178913-26-000637 |
| Exhibit: exhibit_23-2.htm | 0001178913-26-000637 |
| Exhibit: exhibit_23-1.htm | 0001178913-26-000637 |
| Document: 0001178913-26-000637-index-headers.html | 0001178913-26-000637 |
| Document: 0001178913-26-000637-index.html | 0001178913-26-000637 |
| Document: 0001178913-26-000637.txt | 0001178913-26-000637 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 6-K | $5.77 | awaiting T+60 | — | $7.11 (+23.22%) |
Sep 9, 2026 6w ago | 6-K | $8.00 | awaiting T+60 | — | $7.11 (−11.12%) |
Sep 2, 2026 7w ago | EFFECT | $9.60 | awaiting T+60 | — | $7.11 (−25.94%) |
Aug 28, 2026 8w ago | 6-K | $9.87 | awaiting T+60 | — | $7.11 (+27.96%) |
Aug 21, 2026 9w ago | F-1/A | $10.60 | awaiting T+60 | — | $7.11 (−32.92%) |
Aug 17, 2026 10w ago | 6-K | $11.17 | awaiting T+60 | — | $7.11 (−36.35%) |
Aug 14, 2026 10w ago | 6-K | $11.67 | awaiting T+60 | — | $7.11 (−39.07%) |
Jul 22, 2026 13w ago | 6-K | $0.3033 $0.2643 | ▼ −12.85% | ▼ −16.11% | $7.11 (+2244.21%) |
Jul 22, 2026 13w ago | 6-K | $0.3033 $0.2643 | ▼ −12.85% | ▼ −16.11% | $7.11 (+2244.21%) |
Jul 2, 2026 16w ago | 6-K | $0.3765 $0.2240 | ▼ −40.50% | ▼ −43.30% | $7.11 (+1788.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers